| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium Infections, Nontuberculous | 26 | 2023 | 336 | 6.560 |
Why?
|
| Mycobacterium tuberculosis | 20 | 2023 | 268 | 5.540 |
Why?
|
| Tuberculosis | 16 | 2023 | 241 | 5.380 |
Why?
|
| Nontuberculous Mycobacteria | 18 | 2023 | 206 | 3.940 |
Why?
|
| Lung Diseases | 14 | 2023 | 703 | 3.670 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 12 | 2022 | 46 | 3.520 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 7 | 2024 | 76 | 3.140 |
Why?
|
| Tuberculosis, Pulmonary | 14 | 2020 | 112 | 3.050 |
Why?
|
| alpha 1-Antitrypsin | 6 | 2024 | 107 | 2.870 |
Why?
|
| Interleukins | 9 | 2019 | 236 | 2.360 |
Why?
|
| Mycobacterium avium Complex | 8 | 2023 | 92 | 2.270 |
Why?
|
| Antitubercular Agents | 13 | 2022 | 169 | 2.190 |
Why?
|
| Macrophages, Alveolar | 9 | 2020 | 351 | 2.140 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 7 | 2023 | 63 | 2.020 |
Why?
|
| Respiratory Tract Infections | 7 | 2019 | 321 | 1.860 |
Why?
|
| Macrophages | 18 | 2022 | 1266 | 1.810 |
Why?
|
| Smoking | 8 | 2020 | 1391 | 1.300 |
Why?
|
| Glucocorticoids | 3 | 2021 | 534 | 1.260 |
Why?
|
| Lung | 18 | 2023 | 3593 | 1.260 |
Why?
|
| Humans | 131 | 2024 | 114937 | 1.230 |
Why?
|
| Disease Susceptibility | 6 | 2018 | 316 | 1.210 |
Why?
|
| Interferon-gamma | 12 | 2018 | 723 | 1.200 |
Why?
|
| Bronchiectasis | 4 | 2021 | 108 | 1.120 |
Why?
|
| NF-kappa B | 9 | 2022 | 637 | 1.100 |
Why?
|
| Interleukin-8 | 6 | 2022 | 238 | 1.010 |
Why?
|
| Epithelial Cells | 6 | 2020 | 958 | 1.000 |
Why?
|
| Pulmonary Emphysema | 2 | 2024 | 280 | 0.990 |
Why?
|
| Antimicrobial Cationic Peptides | 3 | 2020 | 75 | 0.900 |
Why?
|
| Macrophage Activation | 2 | 2021 | 164 | 0.850 |
Why?
|
| Phospholipids | 4 | 2020 | 197 | 0.850 |
Why?
|
| Critical Care | 2 | 2019 | 474 | 0.840 |
Why?
|
| Nicotine | 3 | 2023 | 266 | 0.830 |
Why?
|
| Mycobacterium | 5 | 2023 | 103 | 0.820 |
Why?
|
| Cigarette Smoking | 1 | 2023 | 74 | 0.810 |
Why?
|
| Edema | 2 | 2017 | 119 | 0.810 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2021 | 25 | 0.810 |
Why?
|
| Latent Tuberculosis | 2 | 2015 | 64 | 0.800 |
Why?
|
| Respiratory Mucosa | 3 | 2020 | 251 | 0.780 |
Why?
|
| Enoxaparin | 1 | 2022 | 52 | 0.770 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2021 | 2326 | 0.770 |
Why?
|
| Apoptosis | 6 | 2020 | 2371 | 0.760 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2022 | 131 | 0.750 |
Why?
|
| Thinness | 2 | 2013 | 87 | 0.750 |
Why?
|
| Angioedema | 1 | 2021 | 16 | 0.740 |
Why?
|
| Lung Neoplasms | 6 | 2021 | 2223 | 0.730 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 3 | 2009 | 6 | 0.720 |
Why?
|
| Sjogren's Syndrome | 1 | 2021 | 42 | 0.720 |
Why?
|
| Angioedemas, Hereditary | 1 | 2020 | 4 | 0.720 |
Why?
|
| Nitric Oxide | 6 | 2017 | 827 | 0.720 |
Why?
|
| Mycobacterium Infections | 5 | 2023 | 61 | 0.700 |
Why?
|
| Immunoassay | 1 | 2020 | 95 | 0.680 |
Why?
|
| Immune Evasion | 1 | 2020 | 47 | 0.680 |
Why?
|
| Funnel Chest | 3 | 2017 | 20 | 0.680 |
Why?
|
| Lipopolysaccharides | 5 | 2022 | 817 | 0.670 |
Why?
|
| Membrane Lipids | 1 | 2020 | 87 | 0.660 |
Why?
|
| Disease Models, Animal | 5 | 2023 | 3549 | 0.660 |
Why?
|
| Smoke | 3 | 2020 | 127 | 0.640 |
Why?
|
| Parasitic Diseases | 1 | 2018 | 6 | 0.630 |
Why?
|
| Lung Diseases, Fungal | 1 | 2018 | 13 | 0.630 |
Why?
|
| Oximetry | 2 | 2013 | 81 | 0.620 |
Why?
|
| Microbial Viability | 3 | 2020 | 79 | 0.610 |
Why?
|
| Pneumonia, Mycoplasma | 3 | 2011 | 30 | 0.610 |
Why?
|
| Granuloma | 3 | 2021 | 84 | 0.590 |
Why?
|
| Anti-Bacterial Agents | 6 | 2016 | 1477 | 0.590 |
Why?
|
| Fluoroquinolones | 3 | 2018 | 41 | 0.590 |
Why?
|
| T-Lymphocytes, Regulatory | 5 | 2023 | 343 | 0.580 |
Why?
|
| Scoliosis | 3 | 2017 | 179 | 0.570 |
Why?
|
| Collateral Circulation | 1 | 2017 | 19 | 0.570 |
Why?
|
| Virulence Factors | 1 | 2018 | 139 | 0.560 |
Why?
|
| Bacterial Infections | 1 | 2018 | 219 | 0.540 |
Why?
|
| Vena Cava, Inferior | 1 | 2017 | 56 | 0.540 |
Why?
|
| Lymphadenopathy | 1 | 2016 | 8 | 0.540 |
Why?
|
| Tularemia | 1 | 2016 | 16 | 0.540 |
Why?
|
| Ciprofloxacin | 1 | 2016 | 23 | 0.540 |
Why?
|
| Francisella tularensis | 1 | 2016 | 19 | 0.540 |
Why?
|
| Acute Pain | 1 | 2017 | 35 | 0.530 |
Why?
|
| Vascular Malformations | 1 | 2017 | 47 | 0.530 |
Why?
|
| Thorax | 1 | 2016 | 41 | 0.530 |
Why?
|
| Hemangioma, Capillary | 2 | 2006 | 13 | 0.530 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2016 | 26 | 0.530 |
Why?
|
| Curcumin | 1 | 2016 | 28 | 0.520 |
Why?
|
| Autophagy | 4 | 2021 | 234 | 0.510 |
Why?
|
| Animals | 31 | 2023 | 31839 | 0.510 |
Why?
|
| Low Back Pain | 1 | 2017 | 95 | 0.500 |
Why?
|
| Models, Biological | 2 | 2020 | 1630 | 0.500 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 142 | 0.490 |
Why?
|
| Biofilms | 6 | 2018 | 223 | 0.490 |
Why?
|
| Mice | 20 | 2023 | 14936 | 0.490 |
Why?
|
| Cerebral Hemorrhage | 1 | 2015 | 96 | 0.470 |
Why?
|
| Cyclonic Storms | 1 | 2015 | 34 | 0.460 |
Why?
|
| Mycobacterium abscessus | 3 | 2021 | 98 | 0.450 |
Why?
|
| Environmental Exposure | 2 | 2015 | 377 | 0.450 |
Why?
|
| Disasters | 1 | 2015 | 88 | 0.450 |
Why?
|
| Somatostatin | 1 | 2013 | 52 | 0.450 |
Why?
|
| Octreotide | 1 | 2013 | 25 | 0.450 |
Why?
|
| Mycobacterium avium | 5 | 2023 | 21 | 0.450 |
Why?
|
| Biomimetic Materials | 1 | 2014 | 64 | 0.450 |
Why?
|
| Risk Factors | 12 | 2021 | 8637 | 0.450 |
Why?
|
| Cell Line | 9 | 2017 | 2640 | 0.440 |
Why?
|
| Interleukin-4 | 3 | 2009 | 208 | 0.440 |
Why?
|
| Amikacin | 2 | 2018 | 20 | 0.430 |
Why?
|
| Chemokine CXCL10 | 2 | 2010 | 34 | 0.420 |
Why?
|
| Diagnosis, Differential | 6 | 2021 | 1355 | 0.410 |
Why?
|
| Transforming Growth Factor beta | 2 | 2013 | 449 | 0.410 |
Why?
|
| Interleukin-18 | 4 | 2011 | 219 | 0.400 |
Why?
|
| Monocytes | 3 | 2011 | 504 | 0.400 |
Why?
|
| Mycoplasma pneumoniae | 2 | 2011 | 28 | 0.400 |
Why?
|
| Tumor Necrosis Factor-alpha | 9 | 2015 | 1134 | 0.400 |
Why?
|
| Nitric Oxide Synthase | 2 | 2003 | 209 | 0.400 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2017 | 2102 | 0.380 |
Why?
|
| Cell Membrane | 2 | 2020 | 679 | 0.370 |
Why?
|
| Chemokine CXCL9 | 1 | 2010 | 21 | 0.370 |
Why?
|
| Male | 38 | 2021 | 55663 | 0.370 |
Why?
|
| Serine Endopeptidases | 2 | 2022 | 102 | 0.370 |
Why?
|
| Respiratory System | 1 | 2011 | 138 | 0.360 |
Why?
|
| Middle Aged | 26 | 2021 | 26806 | 0.360 |
Why?
|
| Bronchi | 2 | 2008 | 243 | 0.330 |
Why?
|
| Streptomycin | 1 | 2009 | 13 | 0.330 |
Why?
|
| Nitric Oxide Synthase Type II | 5 | 2017 | 157 | 0.320 |
Why?
|
| Wound Healing | 1 | 2010 | 258 | 0.310 |
Why?
|
| Virulence | 4 | 2020 | 228 | 0.310 |
Why?
|
| Solitary Fibrous Tumor, Pleural | 1 | 2008 | 3 | 0.310 |
Why?
|
| Osteoarthropathy, Secondary Hypertrophic | 1 | 2008 | 4 | 0.310 |
Why?
|
| Up-Regulation | 3 | 2011 | 812 | 0.300 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2022 | 451 | 0.300 |
Why?
|
| Otitis Media | 1 | 2010 | 143 | 0.300 |
Why?
|
| Female | 37 | 2023 | 59581 | 0.300 |
Why?
|
| Cytokines | 5 | 2023 | 1843 | 0.300 |
Why?
|
| Public Health | 1 | 2012 | 434 | 0.300 |
Why?
|
| Body Mass Index | 4 | 2022 | 1961 | 0.300 |
Why?
|
| Dendritic Cells | 3 | 2021 | 436 | 0.290 |
Why?
|
| Gene Expression | 4 | 2018 | 1422 | 0.290 |
Why?
|
| Comorbidity | 6 | 2021 | 1458 | 0.290 |
Why?
|
| Meningitis, Bacterial | 1 | 2008 | 48 | 0.290 |
Why?
|
| Prevalence | 7 | 2022 | 2252 | 0.290 |
Why?
|
| Cells, Cultured | 8 | 2019 | 3897 | 0.290 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 987 | 0.280 |
Why?
|
| Radiography, Thoracic | 1 | 2008 | 162 | 0.280 |
Why?
|
| Patient Selection | 1 | 2010 | 642 | 0.280 |
Why?
|
| Mycobacteriaceae | 1 | 2007 | 21 | 0.280 |
Why?
|
| Serine Proteinase Inhibitors | 2 | 2022 | 35 | 0.280 |
Why?
|
| Guinea Pigs | 3 | 2020 | 143 | 0.270 |
Why?
|
| Soil Microbiology | 2 | 2020 | 177 | 0.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 1183 | 0.270 |
Why?
|
| Angiomatosis | 1 | 2006 | 4 | 0.270 |
Why?
|
| Adipokines | 2 | 2019 | 42 | 0.270 |
Why?
|
| Immunity, Innate | 3 | 2018 | 725 | 0.270 |
Why?
|
| Immunohistochemistry | 6 | 2011 | 1635 | 0.270 |
Why?
|
| Diagnostic Errors | 2 | 2020 | 151 | 0.270 |
Why?
|
| Promoter Regions, Genetic | 3 | 2009 | 1133 | 0.260 |
Why?
|
| Logistic Models | 4 | 2021 | 1844 | 0.260 |
Why?
|
| Hawaii | 6 | 2023 | 38 | 0.260 |
Why?
|
| Chronic Disease | 3 | 2018 | 1593 | 0.260 |
Why?
|
| Aged | 18 | 2021 | 19122 | 0.260 |
Why?
|
| Dexamethasone | 1 | 2008 | 317 | 0.260 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2021 | 63 | 0.260 |
Why?
|
| Treatment Outcome | 10 | 2022 | 9105 | 0.250 |
Why?
|
| Phosphoproteins | 2 | 2009 | 299 | 0.250 |
Why?
|
| Sodium Chloride | 1 | 2006 | 136 | 0.250 |
Why?
|
| Amino Acid Substitution | 1 | 2006 | 262 | 0.250 |
Why?
|
| Spirometry | 2 | 2024 | 225 | 0.240 |
Why?
|
| Cathelicidins | 3 | 2020 | 38 | 0.240 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2004 | 66 | 0.230 |
Why?
|
| Pulmonary Ventilation | 1 | 2004 | 74 | 0.230 |
Why?
|
| Risk Assessment | 5 | 2021 | 2975 | 0.230 |
Why?
|
| Methylobacterium | 1 | 2023 | 4 | 0.220 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2013 | 797 | 0.220 |
Why?
|
| Bone Marrow Transplantation | 1 | 2004 | 241 | 0.220 |
Why?
|
| Pneumonia, Bacterial | 2 | 2021 | 106 | 0.220 |
Why?
|
| Adaptive Immunity | 2 | 2015 | 157 | 0.220 |
Why?
|
| Nails | 1 | 2003 | 8 | 0.220 |
Why?
|
| Lipids | 2 | 2019 | 582 | 0.220 |
Why?
|
| Wounds and Injuries | 1 | 2010 | 723 | 0.220 |
Why?
|
| Cosmetics | 1 | 2003 | 7 | 0.220 |
Why?
|
| Case-Control Studies | 5 | 2014 | 3008 | 0.220 |
Why?
|
| Molecular Epidemiology | 1 | 2023 | 62 | 0.220 |
Why?
|
| Th1 Cells | 1 | 2004 | 123 | 0.210 |
Why?
|
| Plague | 1 | 2003 | 42 | 0.210 |
Why?
|
| Drinking Water | 3 | 2020 | 64 | 0.210 |
Why?
|
| Angiopoietins | 1 | 2022 | 13 | 0.210 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2006 | 287 | 0.210 |
Why?
|
| Th2 Cells | 1 | 2004 | 154 | 0.210 |
Why?
|
| Adult | 21 | 2023 | 30608 | 0.210 |
Why?
|
| Pancreatic Elastase | 1 | 2022 | 67 | 0.210 |
Why?
|
| Graft vs Host Disease | 1 | 2004 | 215 | 0.210 |
Why?
|
| Soil | 2 | 2022 | 168 | 0.210 |
Why?
|
| Antigens, Bacterial | 1 | 2003 | 112 | 0.210 |
Why?
|
| Gene Expression Regulation | 3 | 2008 | 2324 | 0.200 |
Why?
|
| Fibrillins | 2 | 2013 | 8 | 0.200 |
Why?
|
| Species Specificity | 2 | 2020 | 547 | 0.200 |
Why?
|
| Heparin | 1 | 2023 | 222 | 0.200 |
Why?
|
| Transcription Factor RelA | 2 | 2019 | 83 | 0.190 |
Why?
|
| Autophagosomes | 2 | 2021 | 19 | 0.190 |
Why?
|
| Chest Pain | 2 | 2021 | 81 | 0.190 |
Why?
|
| Tyrosine | 1 | 2002 | 216 | 0.190 |
Why?
|
| HIV Infections | 4 | 2022 | 2470 | 0.190 |
Why?
|
| Phagosomes | 2 | 2019 | 38 | 0.190 |
Why?
|
| Leisure Activities | 1 | 2021 | 24 | 0.180 |
Why?
|
| Prognosis | 5 | 2020 | 3344 | 0.180 |
Why?
|
| Microfilament Proteins | 2 | 2013 | 127 | 0.180 |
Why?
|
| Breast Density | 1 | 2020 | 3 | 0.180 |
Why?
|
| Bronchoalveolar Lavage Fluid | 6 | 2010 | 590 | 0.180 |
Why?
|
| Virus Internalization | 1 | 2020 | 40 | 0.180 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2021 | 71 | 0.180 |
Why?
|
| Bias | 1 | 2021 | 180 | 0.180 |
Why?
|
| Complement C1 Inhibitor Protein | 1 | 2020 | 7 | 0.180 |
Why?
|
| Hemoptysis | 1 | 2021 | 35 | 0.180 |
Why?
|
| Antithrombins | 1 | 2020 | 49 | 0.180 |
Why?
|
| Propensity Score | 1 | 2021 | 224 | 0.180 |
Why?
|
| Extracellular Traps | 1 | 2020 | 40 | 0.180 |
Why?
|
| Leukocyte Elastase | 1 | 2020 | 79 | 0.180 |
Why?
|
| Radiation Tolerance | 1 | 2021 | 92 | 0.180 |
Why?
|
| Radiologists | 1 | 2020 | 39 | 0.180 |
Why?
|
| Chromatography, Thin Layer | 1 | 2020 | 25 | 0.180 |
Why?
|
| THP-1 Cells | 1 | 2020 | 20 | 0.180 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2015 | 217 | 0.170 |
Why?
|
| Leptin | 3 | 2019 | 211 | 0.170 |
Why?
|
| Mammography | 1 | 2020 | 106 | 0.170 |
Why?
|
| Phylogeny | 3 | 2020 | 795 | 0.170 |
Why?
|
| HEK293 Cells | 1 | 2022 | 593 | 0.170 |
Why?
|
| Observer Variation | 1 | 2020 | 297 | 0.170 |
Why?
|
| Protein Subunits | 3 | 2017 | 201 | 0.170 |
Why?
|
| Postmenopause | 2 | 2013 | 303 | 0.170 |
Why?
|
| Retrospective Studies | 7 | 2021 | 12544 | 0.170 |
Why?
|
| Adipose Tissue, White | 1 | 2019 | 27 | 0.170 |
Why?
|
| Pulmonary Surfactants | 2 | 2011 | 101 | 0.170 |
Why?
|
| Lymph Nodes | 2 | 2015 | 425 | 0.160 |
Why?
|
| Vitamin A | 1 | 2019 | 52 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 929 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 152 | 0.160 |
Why?
|
| Dyspnea | 1 | 2021 | 218 | 0.160 |
Why?
|
| Macrolides | 1 | 2019 | 56 | 0.160 |
Why?
|
| DNA-Binding Proteins | 3 | 2016 | 1317 | 0.160 |
Why?
|
| Shock, Septic | 1 | 2021 | 185 | 0.160 |
Why?
|
| Interleukin-12 | 3 | 2011 | 110 | 0.160 |
Why?
|
| Pulmonary Embolism | 2 | 2014 | 183 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 6 | 2021 | 4719 | 0.160 |
Why?
|
| Biota | 1 | 2018 | 35 | 0.160 |
Why?
|
| Leishmania infantum | 1 | 2018 | 4 | 0.160 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2018 | 5 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2015 | 692 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2012 | 278 | 0.150 |
Why?
|
| Emphysema | 1 | 2019 | 110 | 0.150 |
Why?
|
| Enzyme Activation | 4 | 2017 | 790 | 0.150 |
Why?
|
| Protective Factors | 1 | 2018 | 87 | 0.150 |
Why?
|
| Inflammation | 5 | 2019 | 2485 | 0.150 |
Why?
|
| Weight Loss | 2 | 2022 | 642 | 0.150 |
Why?
|
| Cohort Studies | 6 | 2021 | 4903 | 0.150 |
Why?
|
| Adipocytes | 1 | 2019 | 188 | 0.150 |
Why?
|
| Antioxidants | 3 | 2008 | 530 | 0.150 |
Why?
|
| Phenotype | 4 | 2021 | 2817 | 0.150 |
Why?
|
| Fomites | 1 | 2017 | 7 | 0.150 |
Why?
|
| Nicotinic Antagonists | 1 | 2017 | 20 | 0.150 |
Why?
|
| Interleukin-10 | 4 | 2011 | 296 | 0.150 |
Why?
|
| Computer Simulation | 1 | 2021 | 880 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2015 | 966 | 0.140 |
Why?
|
| Mitral Valve Prolapse | 1 | 2017 | 8 | 0.140 |
Why?
|
| Acute Lung Injury | 1 | 2020 | 300 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2021 | 475 | 0.140 |
Why?
|
| Mice, Transgenic | 3 | 2019 | 1953 | 0.140 |
Why?
|
| Wheelchairs | 1 | 2017 | 16 | 0.140 |
Why?
|
| eIF-2 Kinase | 1 | 2017 | 24 | 0.140 |
Why?
|
| Hypoxia | 2 | 2021 | 960 | 0.140 |
Why?
|
| Cancer Survivors | 1 | 2021 | 206 | 0.140 |
Why?
|
| Osmotic Pressure | 1 | 2017 | 28 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2010 | 2096 | 0.140 |
Why?
|
| Interleukin-1beta | 2 | 2009 | 370 | 0.140 |
Why?
|
| Blotting, Western | 2 | 2010 | 1151 | 0.140 |
Why?
|
| Interferon Regulatory Factor-1 | 2 | 2009 | 14 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 642 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 339 | 0.140 |
Why?
|
| Mice, Inbred BALB C | 3 | 2021 | 1153 | 0.140 |
Why?
|
| RNA, Messenger | 4 | 2017 | 2559 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 436 | 0.140 |
Why?
|
| Age Factors | 2 | 2021 | 2891 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2018 | 220 | 0.140 |
Why?
|
| Mobility Limitation | 1 | 2017 | 60 | 0.140 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 6364 | 0.130 |
Why?
|
| Serologic Tests | 1 | 2016 | 49 | 0.130 |
Why?
|
| Postoperative Complications | 2 | 2018 | 2133 | 0.130 |
Why?
|
| Escherichia coli | 1 | 2020 | 722 | 0.130 |
Why?
|
| Regression Analysis | 3 | 2015 | 947 | 0.130 |
Why?
|
| Referral and Consultation | 1 | 2021 | 634 | 0.130 |
Why?
|
| Asthma | 4 | 2008 | 2042 | 0.130 |
Why?
|
| Protective Agents | 1 | 2016 | 38 | 0.130 |
Why?
|
| Testis | 2 | 2009 | 133 | 0.130 |
Why?
|
| Treatment Failure | 2 | 2018 | 332 | 0.130 |
Why?
|
| Sputum | 3 | 2016 | 285 | 0.130 |
Why?
|
| Household Articles | 1 | 2016 | 23 | 0.130 |
Why?
|
| Models, Immunological | 1 | 2016 | 92 | 0.130 |
Why?
|
| Paramyxoviridae Infections | 2 | 2007 | 10 | 0.130 |
Why?
|
| Metapneumovirus | 2 | 2007 | 12 | 0.130 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2015 | 10 | 0.130 |
Why?
|
| Energy-Generating Resources | 1 | 2015 | 5 | 0.130 |
Why?
|
| Antigens, Ly | 1 | 2015 | 45 | 0.120 |
Why?
|
| RNA Splice Sites | 1 | 2015 | 34 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 1 | 2006 | 1737 | 0.120 |
Why?
|
| Leg | 1 | 2017 | 225 | 0.120 |
Why?
|
| Louisiana | 1 | 2015 | 24 | 0.120 |
Why?
|
| Receptors, Nicotinic | 1 | 2017 | 275 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2020 | 647 | 0.120 |
Why?
|
| Bacterial Load | 1 | 2015 | 58 | 0.120 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 1 | 2015 | 42 | 0.120 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 227 | 0.120 |
Why?
|
| Biomass | 1 | 2015 | 108 | 0.120 |
Why?
|
| Systole | 1 | 2015 | 171 | 0.120 |
Why?
|
| Pneumonectomy | 1 | 2016 | 125 | 0.120 |
Why?
|
| Colony Count, Microbial | 1 | 2014 | 111 | 0.120 |
Why?
|
| Critical Illness | 1 | 2019 | 643 | 0.120 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2014 | 47 | 0.120 |
Why?
|
| Phosphorylation | 3 | 2017 | 1572 | 0.120 |
Why?
|
| Transgenes | 1 | 2015 | 170 | 0.120 |
Why?
|
| Calcifediol | 1 | 2014 | 29 | 0.120 |
Why?
|
| International Cooperation | 1 | 2015 | 172 | 0.120 |
Why?
|
| Cytoplasm | 1 | 2015 | 255 | 0.120 |
Why?
|
| Quality of Life | 2 | 2021 | 2359 | 0.110 |
Why?
|
| Tobacco Products | 1 | 2015 | 101 | 0.110 |
Why?
|
| Hepatorenal Syndrome | 1 | 2013 | 14 | 0.110 |
Why?
|
| Calcitriol | 1 | 2014 | 53 | 0.110 |
Why?
|
| Exercise | 2 | 2021 | 1643 | 0.110 |
Why?
|
| Acute Disease | 2 | 2015 | 915 | 0.110 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 954 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 2 | 2008 | 276 | 0.110 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2013 | 31 | 0.110 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2018 | 414 | 0.110 |
Why?
|
| Colorado | 2 | 2021 | 4091 | 0.110 |
Why?
|
| Length of Stay | 1 | 2018 | 949 | 0.110 |
Why?
|
| Pleural Effusion | 1 | 2013 | 47 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 82 | 0.110 |
Why?
|
| Fetal Hemoglobin | 1 | 2013 | 6 | 0.110 |
Why?
|
| Acanthamoeba | 1 | 2013 | 5 | 0.110 |
Why?
|
| Partial Pressure | 1 | 2013 | 30 | 0.110 |
Why?
|
| Pulmonary Edema | 2 | 2004 | 116 | 0.110 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2013 | 10 | 0.110 |
Why?
|
| Marfan Syndrome | 1 | 2013 | 43 | 0.110 |
Why?
|
| Surface Properties | 1 | 2014 | 387 | 0.110 |
Why?
|
| Oxyhemoglobins | 1 | 2013 | 20 | 0.110 |
Why?
|
| Cell Movement | 1 | 2017 | 867 | 0.110 |
Why?
|
| Adolescent | 8 | 2022 | 17829 | 0.110 |
Why?
|
| Thymectomy | 1 | 2012 | 15 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 975 | 0.110 |
Why?
|
| Intracellular Space | 1 | 2013 | 68 | 0.110 |
Why?
|
| Caspase Inhibitors | 1 | 2013 | 78 | 0.110 |
Why?
|
| Thymoma | 1 | 2012 | 30 | 0.110 |
Why?
|
| Transfection | 1 | 2015 | 870 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2014 | 213 | 0.100 |
Why?
|
| Neoplasm Metastasis | 2 | 2014 | 530 | 0.100 |
Why?
|
| Adaptation, Physiological | 1 | 2016 | 483 | 0.100 |
Why?
|
| Cystic Fibrosis | 1 | 2002 | 956 | 0.100 |
Why?
|
| Water Supply | 1 | 2013 | 70 | 0.100 |
Why?
|
| Sulfones | 1 | 2013 | 97 | 0.100 |
Why?
|
| Neutrophil Activation | 1 | 2013 | 94 | 0.100 |
Why?
|
| Water Microbiology | 1 | 2013 | 77 | 0.100 |
Why?
|
| Nitriles | 1 | 2013 | 151 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1325 | 0.100 |
Why?
|
| Biodiversity | 1 | 2016 | 358 | 0.100 |
Why?
|
| Adenoviridae | 1 | 2013 | 185 | 0.100 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2012 | 66 | 0.100 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 446 | 0.100 |
Why?
|
| Caspase 3 | 1 | 2013 | 238 | 0.100 |
Why?
|
| Anti-HIV Agents | 2 | 2018 | 668 | 0.100 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2015 | 301 | 0.100 |
Why?
|
| Bacterial Proteins | 3 | 2016 | 739 | 0.100 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2012 | 122 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2013 | 221 | 0.100 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2010 | 262 | 0.100 |
Why?
|
| Oxidative Stress | 2 | 2010 | 1084 | 0.100 |
Why?
|
| Rifampin | 2 | 2022 | 68 | 0.100 |
Why?
|
| Casein Kinase II | 2 | 2009 | 21 | 0.100 |
Why?
|
| Amino Acid Sequence | 2 | 2013 | 1988 | 0.090 |
Why?
|
| Drug Discovery | 1 | 2012 | 124 | 0.090 |
Why?
|
| United States | 6 | 2022 | 12211 | 0.090 |
Why?
|
| Phosphatidylglycerols | 1 | 2011 | 20 | 0.090 |
Why?
|
| Time Factors | 4 | 2021 | 6125 | 0.090 |
Why?
|
| Liver Failure | 1 | 2011 | 75 | 0.090 |
Why?
|
| RNA, Small Interfering | 2 | 2010 | 543 | 0.090 |
Why?
|
| Blotting, Northern | 1 | 2010 | 193 | 0.090 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2010 | 29 | 0.090 |
Why?
|
| Facial Nerve Diseases | 1 | 2010 | 2 | 0.090 |
Why?
|
| Cerebrospinal Fluid Otorrhea | 1 | 2010 | 5 | 0.090 |
Why?
|
| Earache | 1 | 2010 | 4 | 0.090 |
Why?
|
| Mastoiditis | 1 | 2010 | 5 | 0.090 |
Why?
|
| Eicosanoids | 1 | 2011 | 54 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 509 | 0.090 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 171 | 0.090 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2010 | 22 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2015 | 1125 | 0.090 |
Why?
|
| Temporal Bone | 1 | 2010 | 44 | 0.090 |
Why?
|
| Multiple Myeloma | 1 | 2011 | 93 | 0.090 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2010 | 119 | 0.090 |
Why?
|
| Linezolid | 2 | 2020 | 16 | 0.090 |
Why?
|
| Purpura | 1 | 2009 | 13 | 0.090 |
Why?
|
| In Vitro Techniques | 2 | 2020 | 1034 | 0.090 |
Why?
|
| Transcription, Genetic | 3 | 2016 | 1317 | 0.080 |
Why?
|
| Bacteria | 1 | 2016 | 728 | 0.080 |
Why?
|
| Smoking Prevention | 1 | 2010 | 157 | 0.080 |
Why?
|
| STAT6 Transcription Factor | 1 | 2009 | 22 | 0.080 |
Why?
|
| Lymphocyte Antigen 96 | 1 | 2009 | 24 | 0.080 |
Why?
|
| Arginase | 1 | 2009 | 27 | 0.080 |
Why?
|
| Hypoglycemia | 1 | 2013 | 386 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 1870 | 0.080 |
Why?
|
| Adipose Tissue | 1 | 2012 | 539 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 2542 | 0.080 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2009 | 82 | 0.080 |
Why?
|
| Spleen | 2 | 2008 | 485 | 0.080 |
Why?
|
| Transcriptional Activation | 1 | 2010 | 337 | 0.080 |
Why?
|
| Incidence | 1 | 2015 | 2316 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2015 | 1537 | 0.080 |
Why?
|
| HIV-1 | 1 | 2014 | 768 | 0.080 |
Why?
|
| Oxygen | 1 | 2013 | 853 | 0.080 |
Why?
|
| Gentian Violet | 1 | 2008 | 1 | 0.080 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2008 | 6 | 0.080 |
Why?
|
| Phenazines | 1 | 2008 | 9 | 0.080 |
Why?
|
| Genes, Bacterial | 1 | 2008 | 157 | 0.080 |
Why?
|
| Global Health | 1 | 2010 | 288 | 0.080 |
Why?
|
| Testicular Neoplasms | 1 | 2009 | 97 | 0.080 |
Why?
|
| Metalloporphyrins | 1 | 2008 | 104 | 0.080 |
Why?
|
| Communicable Disease Control | 1 | 2008 | 67 | 0.080 |
Why?
|
| Mutation | 2 | 2017 | 3354 | 0.080 |
Why?
|
| Arginine | 1 | 2009 | 237 | 0.080 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 254 | 0.070 |
Why?
|
| Biomarkers | 4 | 2021 | 3418 | 0.070 |
Why?
|
| Staining and Labeling | 1 | 2008 | 134 | 0.070 |
Why?
|
| Health Status | 2 | 2021 | 721 | 0.070 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2008 | 109 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 1 | 2009 | 151 | 0.070 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 157 | 0.070 |
Why?
|
| Chemotaxis | 1 | 2008 | 130 | 0.070 |
Why?
|
| Pneumonia | 1 | 2012 | 568 | 0.070 |
Why?
|
| Estrogens | 1 | 2010 | 312 | 0.070 |
Why?
|
| Tumor Burden | 2 | 2021 | 262 | 0.070 |
Why?
|
| Obesity | 1 | 2019 | 2514 | 0.070 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2020 | 512 | 0.070 |
Why?
|
| Tricuspid Valve | 1 | 2006 | 25 | 0.070 |
Why?
|
| Child, Preschool | 5 | 2018 | 9086 | 0.070 |
Why?
|
| Fibroma | 1 | 2006 | 21 | 0.070 |
Why?
|
| Cell Transformation, Viral | 1 | 2006 | 24 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2013 | 1354 | 0.070 |
Why?
|
| Heart Neoplasms | 1 | 2006 | 49 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 817 | 0.070 |
Why?
|
| Phenylalanine | 1 | 2006 | 57 | 0.070 |
Why?
|
| Cell Line, Transformed | 1 | 2006 | 133 | 0.060 |
Why?
|
| Nutritional Status | 2 | 2018 | 286 | 0.060 |
Why?
|
| Caspase 1 | 1 | 2006 | 140 | 0.060 |
Why?
|
| Granuloma, Respiratory Tract | 1 | 2005 | 12 | 0.060 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2008 | 299 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1126 | 0.060 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2008 | 384 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 584 | 0.060 |
Why?
|
| Lysosomes | 2 | 2021 | 123 | 0.060 |
Why?
|
| Kartagener Syndrome | 1 | 2005 | 26 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2006 | 285 | 0.060 |
Why?
|
| Radiography | 2 | 2004 | 819 | 0.060 |
Why?
|
| Sex Characteristics | 1 | 2010 | 635 | 0.060 |
Why?
|
| Fatty Acids | 1 | 2008 | 382 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2015 | 6218 | 0.060 |
Why?
|
| Tryptophan | 1 | 2006 | 135 | 0.060 |
Why?
|
| Tracheal Diseases | 1 | 2004 | 15 | 0.060 |
Why?
|
| Lymphocytes | 2 | 2006 | 333 | 0.060 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2007 | 486 | 0.060 |
Why?
|
| Esophageal Diseases | 1 | 2004 | 24 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2010 | 4525 | 0.060 |
Why?
|
| Survival Rate | 1 | 2008 | 1644 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2007 | 729 | 0.060 |
Why?
|
| Body Weight | 2 | 2019 | 868 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 283 | 0.060 |
Why?
|
| Confidence Intervals | 2 | 2021 | 309 | 0.060 |
Why?
|
| Chemokines, CXC | 1 | 2004 | 58 | 0.060 |
Why?
|
| Abnormalities, Multiple | 1 | 2005 | 177 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2010 | 2199 | 0.060 |
Why?
|
| Anthrax | 1 | 2003 | 9 | 0.060 |
Why?
|
| Nuclear Proteins | 2 | 2009 | 593 | 0.050 |
Why?
|
| Callitrichinae | 1 | 2023 | 1 | 0.050 |
Why?
|
| Yersinia pestis | 1 | 2003 | 34 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2023 | 48 | 0.050 |
Why?
|
| Callithrix | 1 | 2023 | 8 | 0.050 |
Why?
|
| 5' Flanking Region | 1 | 2003 | 8 | 0.050 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2003 | 52 | 0.050 |
Why?
|
| Color | 1 | 2003 | 74 | 0.050 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 4407 | 0.050 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 928 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2004 | 524 | 0.050 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2003 | 73 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2010 | 1699 | 0.050 |
Why?
|
| I-kappa B Proteins | 1 | 2003 | 78 | 0.050 |
Why?
|
| Gastroesophageal Reflux | 2 | 2020 | 234 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2002 | 25 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2023 | 490 | 0.050 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2003 | 174 | 0.050 |
Why?
|
| Oxides | 1 | 2022 | 43 | 0.050 |
Why?
|
| Airway Obstruction | 1 | 2004 | 168 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 2004 | 230 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2002 | 184 | 0.050 |
Why?
|
| Epithelium | 1 | 2002 | 298 | 0.050 |
Why?
|
| Child | 5 | 2018 | 18366 | 0.050 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2021 | 18 | 0.050 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2021 | 66 | 0.050 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 39 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2021 | 44 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2003 | 536 | 0.050 |
Why?
|
| Autophagy-Related Proteins | 1 | 2021 | 39 | 0.050 |
Why?
|
| Lymphocyte Depletion | 1 | 2021 | 116 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2003 | 386 | 0.050 |
Why?
|
| Sulfuric Acids | 1 | 2020 | 10 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2004 | 1220 | 0.050 |
Why?
|
| Iron | 1 | 2022 | 233 | 0.040 |
Why?
|
| Recurrence | 2 | 2018 | 937 | 0.040 |
Why?
|
| Biological Assay | 1 | 2021 | 113 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2008 | 1530 | 0.040 |
Why?
|
| Pulmonary Artery | 1 | 2006 | 1028 | 0.040 |
Why?
|
| Intensive Care Units | 2 | 2021 | 619 | 0.040 |
Why?
|
| Superoxides | 2 | 2013 | 214 | 0.040 |
Why?
|
| Respiratory Aspiration | 1 | 2020 | 31 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 1440 | 0.040 |
Why?
|
| China | 1 | 2020 | 162 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 149 | 0.040 |
Why?
|
| Australia | 1 | 2020 | 207 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2021 | 217 | 0.040 |
Why?
|
| 3-Hydroxysteroid Dehydrogenases | 1 | 2019 | 9 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2005 | 1054 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 3053 | 0.040 |
Why?
|
| Retinal Dehydrogenase | 1 | 2019 | 41 | 0.040 |
Why?
|
| Bacillus | 1 | 2019 | 14 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 2019 | 105 | 0.040 |
Why?
|
| Insurance Claim Review | 1 | 2019 | 67 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 448 | 0.040 |
Why?
|
| Cell Wall | 1 | 2019 | 52 | 0.040 |
Why?
|
| Topography, Medical | 1 | 2018 | 12 | 0.040 |
Why?
|
| Kanamycin | 1 | 2018 | 8 | 0.040 |
Why?
|
| Capreomycin | 1 | 2018 | 2 | 0.040 |
Why?
|
| Diarylquinolines | 1 | 2018 | 5 | 0.040 |
Why?
|
| Carbapenems | 1 | 2018 | 16 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2004 | 772 | 0.040 |
Why?
|
| Levofloxacin | 1 | 2018 | 22 | 0.040 |
Why?
|
| Clofazimine | 1 | 2018 | 14 | 0.040 |
Why?
|
| Child Nutrition Disorders | 1 | 2018 | 16 | 0.040 |
Why?
|
| Hyperinsulinism | 1 | 2019 | 103 | 0.040 |
Why?
|
| Health Services | 1 | 2019 | 103 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2018 | 26 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2004 | 655 | 0.040 |
Why?
|
| Early Ambulation | 1 | 2018 | 14 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 434 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 1080 | 0.040 |
Why?
|
| Proteomics | 1 | 2004 | 844 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2021 | 368 | 0.040 |
Why?
|
| Health Resources | 1 | 2019 | 122 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 336 | 0.040 |
Why?
|
| Health Expenditures | 1 | 2019 | 171 | 0.040 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2018 | 97 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 1180 | 0.040 |
Why?
|
| Malnutrition | 1 | 2018 | 61 | 0.040 |
Why?
|
| Interleukin-1 | 1 | 2002 | 966 | 0.040 |
Why?
|
| Sepsis | 1 | 2003 | 508 | 0.040 |
Why?
|
| Family Characteristics | 1 | 2018 | 152 | 0.040 |
Why?
|
| Nitrosation | 1 | 2017 | 8 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 249 | 0.040 |
Why?
|
| Enterocytes | 1 | 2017 | 14 | 0.040 |
Why?
|
| Coinfection | 1 | 2018 | 120 | 0.040 |
Why?
|
| Self Report | 1 | 2021 | 696 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 1081 | 0.030 |
Why?
|
| RNA, Double-Stranded | 1 | 2017 | 44 | 0.030 |
Why?
|
| Gambia | 1 | 2016 | 12 | 0.030 |
Why?
|
| Age of Onset | 1 | 2018 | 448 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2011 | 113 | 0.030 |
Why?
|
| Two-Hybrid System Techniques | 2 | 2009 | 52 | 0.030 |
Why?
|
| Uganda | 1 | 2016 | 70 | 0.030 |
Why?
|
| Regulon | 1 | 2016 | 32 | 0.030 |
Why?
|
| Models, Animal | 1 | 2018 | 346 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2004 | 891 | 0.030 |
Why?
|
| Nitrogen Oxides | 1 | 2016 | 47 | 0.030 |
Why?
|
| Infant | 3 | 2007 | 7937 | 0.030 |
Why?
|
| Baths | 1 | 2016 | 17 | 0.030 |
Why?
|
| Syndrome | 1 | 2017 | 336 | 0.030 |
Why?
|
| Metabolic Syndrome | 1 | 2019 | 323 | 0.030 |
Why?
|
| Humidity | 1 | 2016 | 37 | 0.030 |
Why?
|
| Program Development | 1 | 2018 | 345 | 0.030 |
Why?
|
| Family Health | 1 | 2017 | 194 | 0.030 |
Why?
|
| Pedigree | 1 | 2017 | 467 | 0.030 |
Why?
|
| Housing | 1 | 2016 | 114 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2018 | 276 | 0.030 |
Why?
|
| Mental Health | 1 | 2021 | 559 | 0.030 |
Why?
|
| Science | 1 | 2016 | 48 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 648 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2019 | 490 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2017 | 295 | 0.030 |
Why?
|
| Ethiodized Oil | 1 | 2014 | 5 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2021 | 2587 | 0.030 |
Why?
|
| Hepatic Artery | 1 | 2014 | 48 | 0.030 |
Why?
|
| Dyneins | 2 | 2005 | 29 | 0.030 |
Why?
|
| Colitis | 1 | 2017 | 226 | 0.030 |
Why?
|
| Protein Kinases | 1 | 2016 | 307 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 2725 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 572 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2015 | 155 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 583 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2018 | 374 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 1721 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 675 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2020 | 901 | 0.030 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2014 | 80 | 0.030 |
Why?
|
| Hartmannella | 1 | 2013 | 2 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2014 | 286 | 0.030 |
Why?
|
| Rituximab | 1 | 2013 | 151 | 0.030 |
Why?
|
| Water | 1 | 2016 | 399 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2013 | 201 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1400 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 954 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2011 | 52 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2011 | 14 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2011 | 57 | 0.020 |
Why?
|
| Students | 1 | 2016 | 500 | 0.020 |
Why?
|
| Liver | 2 | 2011 | 1634 | 0.020 |
Why?
|
| Group IV Phospholipases A2 | 1 | 2011 | 45 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2010 | 41 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2010 | 78 | 0.020 |
Why?
|
| Catalase | 1 | 2010 | 117 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 1813 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2011 | 164 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2016 | 585 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 165 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2011 | 166 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2011 | 160 | 0.020 |
Why?
|
| Cysteine | 1 | 2011 | 171 | 0.020 |
Why?
|
| U937 Cells | 1 | 2009 | 22 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2010 | 142 | 0.020 |
Why?
|
| Spermatids | 1 | 2009 | 18 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 271 | 0.020 |
Why?
|
| Blood Cells | 1 | 2009 | 38 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2003 | 2791 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2010 | 305 | 0.020 |
Why?
|
| Environment | 1 | 2010 | 334 | 0.020 |
Why?
|
| Staphylococcus epidermidis | 1 | 2009 | 71 | 0.020 |
Why?
|
| Hospitals | 1 | 2013 | 581 | 0.020 |
Why?
|
| Ecosystem | 1 | 2013 | 516 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 596 | 0.020 |
Why?
|
| Fimbriae, Bacterial | 1 | 2008 | 25 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 1087 | 0.020 |
Why?
|
| Biopsy | 1 | 2011 | 1045 | 0.020 |
Why?
|
| Saskatchewan | 1 | 2007 | 7 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2010 | 927 | 0.020 |
Why?
|
| Nucleocapsid Proteins | 1 | 2007 | 24 | 0.020 |
Why?
|
| X-Rays | 1 | 2007 | 30 | 0.020 |
Why?
|
| DNA, Ribosomal | 1 | 2007 | 80 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2008 | 352 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2008 | 438 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2009 | 286 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2007 | 138 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 1523 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1856 | 0.020 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2006 | 89 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 744 | 0.020 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2008 | 285 | 0.020 |
Why?
|
| Axonemal Dyneins | 1 | 2005 | 8 | 0.020 |
Why?
|
| Mice, Obese | 1 | 2005 | 53 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2007 | 310 | 0.020 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 2005 | 21 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2006 | 339 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2005 | 113 | 0.020 |
Why?
|
| Nasal Mucosa | 1 | 2005 | 93 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2005 | 297 | 0.010 |
Why?
|
| Health Services Administration | 1 | 2004 | 7 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 2211 | 0.010 |
Why?
|
| Extravascular Lung Water | 1 | 2004 | 8 | 0.010 |
Why?
|
| Nitrites | 1 | 2004 | 74 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2004 | 101 | 0.010 |
Why?
|
| Viral Fusion Proteins | 1 | 2003 | 20 | 0.010 |
Why?
|
| t-Complex Genome Region | 1 | 2003 | 3 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 1233 | 0.010 |
Why?
|
| Testicular Hormones | 1 | 2003 | 9 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 1897 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2007 | 522 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 2004 | 110 | 0.010 |
Why?
|
| Demography | 1 | 2004 | 262 | 0.010 |
Why?
|
| Deglutition Disorders | 1 | 2004 | 120 | 0.010 |
Why?
|
| Uric Acid | 1 | 2004 | 148 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2003 | 285 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 293 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2003 | 325 | 0.010 |
Why?
|
| Glutathione | 1 | 2004 | 300 | 0.010 |
Why?
|
| Probability | 1 | 2003 | 291 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 387 | 0.010 |
Why?
|
| Canada | 1 | 2003 | 322 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2003 | 139 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 2002 | 44 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2002 | 84 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 741 | 0.010 |
Why?
|
| Indomethacin | 1 | 2002 | 74 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2005 | 633 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2004 | 233 | 0.010 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2002 | 72 | 0.010 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2002 | 66 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 144 | 0.010 |
Why?
|
| Injury Severity Score | 1 | 2003 | 457 | 0.010 |
Why?
|
| Dinoprostone | 1 | 2002 | 184 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 4963 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2002 | 267 | 0.010 |
Why?
|
| Imidazoles | 1 | 2002 | 211 | 0.010 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2004 | 557 | 0.010 |
Why?
|
| Proteome | 1 | 2004 | 339 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 759 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2002 | 400 | 0.010 |
Why?
|
| Base Sequence | 1 | 2003 | 2118 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 1700 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 752 | 0.010 |
Why?
|
| Pyridines | 1 | 2002 | 425 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 611 | 0.010 |
Why?
|
| Proteins | 1 | 2004 | 912 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2002 | 676 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 10478 | 0.010 |
Why?
|
| Veterans | 1 | 2004 | 1240 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2004 | 4635 | 0.010 |
Why?
|